EC Number   |
Application |
Reference |
|---|
   3.4.21.77 | analysis |
development and employment of counter-SELEX (systematic evolution of ligands by exponential enrichment) procedures to identify specific RNA aptamers against the purified active PSA, wich is not only a specific marker but also a target molecule for diagnosis and therapy of prostate cancer. The aptamers have a specific binding activity against the active PSA, but not for GST or proPSA |
707822 |
| 3.4.21.77 | analysis |
development of a simultaneous electrochemical biosensor, using the goldmodified screen-printed carbon dual sensor, for free and total PSA for monitoring PSA production from three different cultures of human androgen-sensitive prostate tumor cells |
707800 |
| 3.4.21.77 | analysis |
development of an electrical immunosensor for the detection of PSA using a microgapped electrode array based on enzymatic silver deposition. This electrical immunosensor exhibits a linear response with PSA concentrations over a 6-decade range from 1.0 pg/l to 1.0 microg/l, with detection limit of 0.9 pg/l. PSA concentrations using this immunosensor agree within 10% of those obtained using a commercial chemiluminescent immunoassay |
708169 |
| 3.4.21.77 | analysis |
development of PSA and Fab anti-PSA biosensor arrays using UV light-assisted molecular immobilization LAMI, aiming at the detection and quantification of PSA, as a cancer marker. The technology involves formation of free, reactive thiol groups upon UV excitation of protein aromatic residues located in spatial proximity of disulfide bridges, conserved in both PSA and Fab molecules. The thiol groups bind onto thiol reactive surfaces leading to oriented covalent protein immobilization. LAMI technology is successful in immobilizing biomedically relevant molecules while preserving their activity |
718365 |
| 3.4.21.77 | analysis |
mass spectrometry annotation can identify more molecular forms of PSA compared with Western and zymographic analyses. Observation of various isoforms of PSA in patients may contribute to the further identification of disease-relevant heterogeneity of PSA, including transcriptional and post-translational modifications present due to various stages and causes of prostate disease |
709704 |
| 3.4.21.77 | analysis |
real-time detection of prostate-specific antigen PSA in diluted human serum without labeling by use of an amplitude-sensitive paired surface plasma wave biosensor PSPWB. The detection limit of PSPWB is 8.4 × 10-9 refractive index units, and the PSPWB can measure PSA in a phosphate buffered saline solution from 10 fg/ml to 100 pg/ml, i.e. about 3 pM, successfully, with a linear relationship between PSA concentrations and surface plasmon resonance signals. The PSPWB successfully detects PSA in diluted human serum as well |
717086 |
| 3.4.21.77 | diagnostics |
concentration of enzyme in nonprostatic tissue represents less than 1% of the amount in normal prostate. Thus enzyme released from sources other than the prostate may add to the plasma pool, but it is unlikely that nonprostatic enzyme normally can interfere with the diagnosis of prostate cancer |
665230 |
| 3.4.21.77 | diagnostics |
the enzyme is the most useful prostate cancer marker |
732851 |
| 3.4.21.77 | diagnostics |
the gama-SM/PSA, a protein member of the kallikrein family, is the most prominent biomarker for prostate cancer, PCa. Hsp70 can also be used as a co-biomarker for PCa with gama-SM |
753651 |
| 3.4.21.77 | diagnostics |
the ratio of phosphorylated/dephosphorylated galectin-3 might be used as a complementary value to that of prostate specific antigene for prognosis of prostate cancer and another therapeutic target for the treatment of prostate cancer |
731135 |
